- info@ivshop.co.za
- Available Nationwide
R3 499,00
Tesamorelin is a stabilized, synthetic peptide analogue of human growth hormone-releasing hormone (GHRH). By stimulating the pituitary gland to release endogenous growth hormone (GH), it significantly increases insulin-like growth factor-1 (IGF-1) levels. This action helps regulate body composition, specifically targeting visceral adipose tissue (fat around internal organs)
Fast, tracked shipping across South Africa.
Doctor-approved, pharmacy-sourced wellness products.
Encrypted checkout with trusted gateways.
Tesamorelin binds to the GHRH receptor in the anterior pituitary, increasing the amplitude and frequency of natural GH pulses. This elevates systemic IGF-1 levels and influences lipolytic, metabolic, and tissue-signaling pathways.
• Dose: 7 mg vial: intended for a 1 mg daily dose
• Duration: 12–24 weeks
• Each vial is used over 7 days.
• Reconstitute with 3.5 ml diluent.
• Administer 0.5 ml once daily.
Monthly Supply Structure: Each purchase constitutes a one-month supply and includes:
• 4 x Tesamorelin vials at the prescribed strength (7 mg)
• One pH specific bacteriostatic multidose water vial
• The bacteriostatic water supplied is sufficient to reconstitute all four Tesamorelin vials provided for the month. Storage Conditions: Unreconstituted Tesamorelin Powder
• Store frozen at −21 °C. Maintain frozen storage until ready for reconstitution. pH Specific Bacteriostatic Water
• Store at controlled room temperature between 20 and 25 °C. Do not freeze. After Reconstitution
• Store refrigerated and use within 7 days. Reconstitution Instructions
(IMPORTANT)
1. Remove one Tesamorelin vial from the freezer and allow it to reach room temperature before reconstitution. Do not apply heat to accelerate warming.
2. Wash hands thoroughly.
3. Clean the rubber stoppers of both the Tesamorelin vial and the bacteriostatic water vial with an alcohol swab and allow to dry.
4. Using a sterile syringe and needle, withdraw exactly 3.5 ml of the pH specific bacteriostatic water.
5. Insert the needle into the Tesamorelin vial and slowly inject the 3.5 ml diluent down the inside wall of the vial. Avoid injecting forcefully directly onto the powder.
6. Do NOT shake the vial. Shaking may cause foaming and peptide degradation.
7. Gently roll the vial between the palms or swirl carefully until the powder is fully dissolved. This may take a few minutes.
8. The solution should appear clear and free of visible particles. If cloudy or particulate matter is observed, do not use.
9. After reconstitution, store the vial in the refrigerator.
10. For each dose, clean the stopper with alcohol before withdrawing 0.5 ml. Use a new sterile needle and syringe for every administration.
Additional Notes:
• Each vial is intended for single patient use only.
• Do not pre-reconstitute multiple vials in advance.
• Maintain sterile technique at all times.
• Based on its storage requirement of −21 °C in the dry state and its stability profile once in solution, maintaining Tesamorelin as a powder until point of use allows tighter control over:
• Cold chain integrity
• Shelf stability prior to reconstitution
• Predictable 7 day in use period post reconstitution
A prefilled pen configuration would require the product to remain in solution for extended periods, which does not align with the validated stability parameters we are working within for this molecule. The current format therefore supports product stability and dosing consistency within the assigned storage conditions.
Specific Side Effects:
Peripheral edema
NOT SUITABLE FOR PATIENTS WITH CANCER
7 mg VIAL x 4 = 28 mg 1 mg daily dose
Tesamorelin exposure has been associated with:
Reviews
There are no reviews yet.